Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small cell lung cancer

  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • de Maya-Gironés, J.D.
  • Calabuig-Fariñas, Silvia
  • Lucas, Rut
  • Martínez-Romero, Alicia
  • Pardo-Sánchez, José Miguel
  • Alonso, Sergio
  • Blasco-Cordellat, Ana
  • Guijarro, Ricardo
  • Martorell, Miguel
  • Escorihuela, Eva
  • Chiara, María Dolores
  • Durendez-Saez, Elena
  • Gandía, Carolina
  • Forteza, Jerónimo
  • Farràs, Rosa
  • Camps-Herrero, Carlos
[EN] The high resistance against current therapies found in non-small-cell lung cancer (NSCLC) has been associated to cancer stem-like cells (CSCs), a population for which the identification of targets and biomarkers is still under development. In this study, primary cultures from early-stage NSCLC patients were established, using sphere-forming assays for CSC enrichment and adherent conditions for the control counterparts. Patient-derived tumorspheres showed self-renewal and unlimited exponential growth potentials, resistance against chemotherapeutic agents, invasion and differentiation capacities in vitro, and superior tumorigenic potential in vivo. Using quantitative PCR, gene expression profiles were analyzed and NANOG, NOTCH3, CD44, CDKN1A, SNAI1, and ITGA6 were selected to distinguish tumorspheres from adherent cells. Immunoblot and immunofluorescence analyses confirmed that proteins encoded by these genes were consistently increased in tumorspheres from adenocarcinoma patients and showed differential localization and expression patterns. The prognostic role of genes significantly overexpressed in tumorspheres was evaluated in a NSCLC cohort (N = 661) from The Cancer Genome Atlas. Based on a Cox regression analysis, CDKN1A, SNAI1, and ITGA6 were found to be associated with prognosis and used to calculate a gene expression score, named CSC score. Kaplan¿Meier survival analysis showed that patients with high CSC score have shorter overall survival (OS) in the entire cohort [37.7 vs. 60.4 months (mo), p = 0.001] and the adenocarcinoma subcohort [36.6 vs. 53.5 mo, p = 0.003], but not in the squamous cell carcinoma one. Multivariate analysis indicated that this gene expression score is an independent biomarker of prognosis for OS in both the entire cohort [hazard ratio (HR): 1.498; 95% confidence interval (CI), 1.167¿1.922; p = 0.001] and the adenocarcinoma subcohort [HR: 1.869; 95% CI, 1.275¿2.738; p = 0.001]. This score was also analyzed in an independent cohort of 114 adenocarcinoma patients, confirming its prognostic value [42.90 vs. not reached (NR) mo, p = 0.020]. In conclusion, our findings provide relevant prognostic information for lung adenocarcinoma patients and the basis for developing novel therapies. Further studies are required to identify suitable markers and targets for lung squamous cell carcinoma patients., This work was supported by Fondo de Investigación Sanitaria, ISCIII (PI12-02838, PI12-00956, PI15-00753, PI15-00209), and Fundación Arnal Planelles. A. H.-P. and J.M.P.-S. are supported by Ministerio de Educación, Cultura y Deporte (FPU14/06911 and FPU13/02755, respectively).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

  • Moreno-Manuel, Andrea
  • Simoes, Ines
  • Aranda, Fernando
  • Calabuig-Fariñas, Silvia
  • Carreras, Esther
  • Zuñiga, Sheila
  • Saenger, Yvone
  • Rosell, Rafael
  • Camps-Herrero, Carlos
  • Lozano, Francisco
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
[EN] Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6¿two lymphocyte surface markers involved in the fine tuning of TCR signaling¿as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC). Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360¿0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression¿ although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort. Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance., This work was supported by Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria; PI15-00753 to RS and P118/00226 to EJ and CC), Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Plan Nacional de I+D+i; SAF2016-80535-R to FL) -co-financed by European Development Regional Fund "A way to achieve Europe" ERDF; Worldwide Cancer Research (14-1275 to FL), Fundacio La Marato TV3 (201319-30-31-32 to FL and YS), and Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya (2017/SGR/1582 to FL). AM is recipient of a PhD scholarship from Asociacion Espanola Contra el Cancer (AECC) Scientific Foundation and Junta Provincial Asociada de Valencia AECC; IS, FA and EC are recipients of fellowships from Fundacao para a Ciencia e a Tecnologia (SFRH/BD/75738/2011), Sara Borrell Program from ISCIII (CD15/00016), and European Community Seventh Framework Program (BIOTRACK, FP7/2007/2013; 229673), respectively.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

TMPRSS4: a novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for NSCLC patients

  • Villalba, María
  • Expósito, Francisco
  • Pajares Villandiego, María Josefa
  • Sáinz, Cristina
  • Redrado, Miriam
  • Remírez, Ana
  • Wistuba, Ignacio
  • Behrens, Carmen
  • Jantus-Lewintre, Eloisa
  • Camps, Carlos
  • Montuenga, Luis M.
  • Pío, Rubén
  • Lozano, María Dolores
  • Andrea, Carlos de
  • Calvo, Alfonso
Relapse rates in surgically resected non-small-cell lung cancer (NSCLC) patients are between 30% and 45% within five years of diagnosis, which shows the clinical need to identify those patients at high risk of recurrence. The eighth TNM staging system recently refined the classification of NSCLC patients and their associated prognosis, but molecular biomarkers could improve the heterogeneous outcomes found within each stage. Here, using two independent cohorts (MDA and CIMA-CUN) and the eighth TNM classification, we show that TMPRSS4 protein expression is an independent prognostic factor in NSCLC, particularly for patients at stage I: relapse-free survival (RFS) HR, 2.42 (95% CI, 1.47–3.99), p < 0.001; overall survival (OS) HR, 1.99 (95% CI, 1.25–3.16), p = 0.004). In stage IA, high levels of this protein remained associated with worse prognosis (p = 0.002 for RFS and p = 0.001 for OS). As TMPRSS4 expression is epigenetically regulated, methylation status could be used in circulating tumor DNA from liquid biopsies to monitor patients. We developed a digital droplet PCR (ddPCR) method to quantify absolute copy numbers of methylated and unmethylated CpGs within the TMPRSS4 and SHOX2 (as control) promoters in plasma and bronchoalveolar lavage (BAL) samples. In case-control studies, we demonstrated that TMPRSS4 hypomethylation can be used as a diagnostic tool in early stages, with an AUROC of 0.72 (p = 0.008; 91% specificity and 52% sensitivity) for BAL and 0.73 (p = 0.015; 65% specificity and 90% sensitivity) for plasma, in early stages. In conclusion, TMPRSS4 protein expression can be used to stratify patients at high risk of relapse/death in very early stages NSCLC patients. Moreover, analysis of TMPRSS4 methylation status by ddPCR in blood and BAL is feasible and could serve as a non-invasive biomarker to monitor surgically resected patients., This work has been funded by PIUNA to C.A., ISC-III (PI16/01352, to A.C.; PI17/0041 to R.P.; PI15/00753; PI16/01821 to L.M.M., and CB16/12/00350 to E.J.L.; CIBERONC CB16/12/00443 to L.M.M.), Juan Serrano, AECC, and Ramón Areces Foundations (to L.M.M.).M.V. was supported by “FPU, Spanish Ministry of Education”; F.E. was funded by "Asociación de Amigos de la Universidad de Navarra" in association with "La Caixa" Banking Foundation.